Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sunitinib.

Brian I Rini1

  • 1Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue/Desk R35, Cleveland, Ohio 44195, USA. rinib2@ccf.org

Expert Opinion on Pharmacotherapy
|October 12, 2007
PubMed
Summary
This summary is machine-generated.

Sunitinib, a receptor tyrosine kinase inhibitor, shows significant antitumor effects in advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Further research is needed to optimize its use in various solid tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sunitinib targets receptor tyrosine kinases involved in tumor angiogenesis, such as the vascular endothelial growth factor (VEGF) receptor.
  • In vitro and murine models demonstrate potent inhibition and antiangiogenic effects of sunitinib.

Purpose of the Study:

  • To summarize the efficacy and tolerability of sunitinib in clinical studies.
  • To highlight its approved indications and ongoing investigations in solid tumors.

Main Methods:

  • Review of in vitro and murine model data.
  • Analysis of human clinical trial results for sunitinib dosing and efficacy.
  • Summary of regulatory approvals and ongoing investigations.

Main Results:

Related Experiment Videos

  • Sunitinib is a well-tolerated small-molecule inhibitor at a 50 mg daily intermittent dose.
  • Significant antitumor activity observed in advanced renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

Conclusions:

  • Sunitinib is approved for RCC and GIST, demonstrating significant clinical benefit.
  • Ongoing investigations explore sunitinib's potential across a wider range of solid tumors.
  • Further research is required to fully optimize sunitinib's therapeutic utility.